Andexanet for Factor Xa Inhibitor–Associated ...

Is the "Cytokine Storm" the Real Killer in ARDS? When a localized lung injury spirals into a systemic catastrophe, we call it a cytokine storm—but are we actually any closer to stopping it, or are we just watching the rain? This deep-dive review, published in the Journal of Inten ...  Show more

Can we break the cycle of Diuretic Resistance? What do you do when the "gold standard" treatment for your congested patient simply stops working? Diuretic resistance (DR) affects up to one-third of patients with heart failure, turning a routine clinical task into a high-stakes ba ...  Show more

The SMART-CHOICE 3 trial demonstrated that clopidogrel monotherapy is more effective than aspirin monotherapy in reducing the risk of major adverse cardiac and cerebrovascular events in high-risk patients who completed standard dual antiplatelet therapy (DAPT) following percutane ...  Show more

In this episode, Dr. Valentin Fuster discusses the findings of a major randomized trial examining the use of drug-coated balloons (DCB) in treating side branch stenosis during coronary bifurcation procedures. The study suggests that DCBs offer better one-year outcomes compared to ...  Show more

<span style="mso-bidi-font-weight: bold;">If a patient with a traumatic brain injury is exhibiting aggressive behavior, which of the following intervention strat ...

Once the diagnosis of nontraumatic subarachnoid hemorrhage (SAH) has been made, our job is not done. Mortality in SAH patients can be up to 30% even without neurological deficit. Paying attention to the time-sensitive details of ED management of SAH patients can have a significan ...  Show more